J Clin Lipidol:极高水平HDL-C对病因特异性CVD死亡率的影响

2018-06-29 王淳 环球医学

2018年5月,发表在《J Clin Lipidol》的一项由日本学者进行的汇总分析,考察了极高水平高密度脂蛋白胆固醇(HDL-C)与心血管疾病(CVD)死亡率的相关性。

2018年5月,发表在《J Clin Lipidol》的一项由日本学者进行的汇总分析,考察了极高水平高密度脂蛋白胆固醇(HDL-C)与心血管疾病(CVD)死亡率的相关性。

背景:非常高或极高水平HDL-C对CVD的影响还未被很好地描述。虽然近期有少量研究报道了极高水平HDL-C对CVD事件具有不良影响,但是这些研究并未显示出极高水平HDL-C和病因特异性CVD死亡率之间具有统计学显着的相关性。此外,还未有研究考察过亚洲人群的情况。

目的:旨在使用日本队列研究的汇总数据考察极高水平HDL-C对病因特异性CVD死亡率的影响。

方法:研究人员对9项日本队列研究进行大样本荟萃分析,共计纳入43407名40~89岁的参与者,并根据HDL-C水平将参与者分为5组,包括极高水平HDL-C≥2.33mmol/L(≥90mg/dL)。研究人员使用队列分层的Cox比例风险模型评估了与1.04~1.55mmol/L(40~59mg/dL)的HDL-C分组参与者相比,各HDL-C类别全因死亡和病因特异性死亡的调整风险比(HR)。

结果:经过12.1年的随访,鉴别出4995例全因死亡和1280例CVD造成的死亡。极高水平HDL-C与动脉粥样硬化性CVD死亡风险的增加(HR,2.37;95% 置信区间[CI],1.37~4.09)和冠心病及缺血性卒中风险的增加显着相关。此外,极高水平HDL-C的风险在目前饮酒者中更显着。

结论:日本队列的荟萃分析显示,极高水平HDL-C对动脉粥样硬化性CVD死亡率具有不良影响。

原始出处:

Hirata A, Sugiyama D, Watanabe M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol. 2018 May - Jun;12(3):674-684.e5. doi: 10.1016/j.jacl.2018.01.014. Epub 2018 Feb 8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-10-16 tongyongming
  2. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2019-03-18 bettycmoon
  3. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-07-01 ZGMFX24A
  6. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1703514, encodeId=585d1e0351498, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Oct 16 22:58:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656389, encodeId=5f75165638954, content=<a href='/topic/show?id=6e6a1091e1e' target=_blank style='color:#2F92EE;'>#Lipid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10917, encryptionId=6e6a1091e1e, topicName=Lipid)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66a524807292, createdName=bettycmoon, createdTime=Mon Mar 18 22:58:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799517, encodeId=ea6f1e99517d5, content=<a href='/topic/show?id=b8d7e08467a' target=_blank style='color:#2F92EE;'>#病因特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70846, encryptionId=b8d7e08467a, topicName=病因特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Sat Jan 12 16:58:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899225, encodeId=1f1718992251e, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sat Aug 25 13:58:00 CST 2018, time=2018-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316433, encodeId=9fe61316433e5, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480827, encodeId=6bc0148082eaf, content=<a href='/topic/show?id=edd28609dd' target=_blank style='color:#2F92EE;'>#HDL-C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8609, encryptionId=edd28609dd, topicName=HDL-C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0a97689161, createdName=ms920641618706883, createdTime=Sun Jul 01 02:58:00 CST 2018, time=2018-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328018, encodeId=3baa32801835, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Jun 29 21:03:58 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-29 smartxiuxiu

    0

相关资讯

Chest:可视化估计的冠状动脉钙化可预测COPD患者心血管疾病!

由此可见,CAC的简单视觉评分在预测患有COPD和不患有COPD的吸烟者CAD事件具有很好的效果。

JAHA:青年人总胆固醇水平变化对心血管疾病的影响!

由此可见,该研究的结果表明,胆固醇水平升高与年轻人的升高的CVD风险有关。此外,胆固醇水平降低的年轻人心血管疾病的风险降低。

Heart:婚姻状况与心血管疾病风险!

由此可见,婚姻状况对CVD以及CVD预后有影响。这些结果可能表明婚姻状况应考虑在CVD和CVD结局的风险评估。

美国心血管疾病治疗方案数据过时 上千万人或吃错药

澳媒称,一项新的研究显示,超过1100万美国人使用的阿司匹林、斯达汀和血压药物处方可能是不正确的。据澳大利亚科学预警网站6月10日报道,研究人员根据一套更新后的计算方法得出了这一结论,这套被称为“汇集队列方程”(PCEs)的计算方法被用来确定发生心脏病和中风的风险。报道称,PCEs是美国心脏血管疾病预防指导原则的基础。通过评估患者可能患心脏病或中风的风险,它们帮助医生判断是否给病人开出阿司匹林、血

J Clin Lipidol:ω-3脂肪酸可以降低死亡和心血管疾病风险吗?

ω-3脂肪酸水平与任何原因的死亡风险和心血管疾病(CVD)发病风险相关到何种程度仍然有争议。2018年5月,发表在《J Clin Lipidol》的一项前瞻性和观察性研究调查了红细胞长链ω-3脂肪酸水平与死亡率和心血管疾病发病风险的相关性。

PLOS ONE:心血管疾病高风险患者的慢性肾脏疾病情况

慢性肾脏疾病已成为越来越重要的临床和公共健康问题,在全球引起的死亡人数约为110万。